Close

move up move left move right move bottom

XARELTO® Starter Pack

The only pack available for initiation of DVT and/or PE treatment

The treatment you know in a convenient package

  • Provides therapy for the first 30 days when patients are most vulnerable to a recurrent event1
  • Helps provide a seamless transition from diagnosis to follow-up
  • A single-agent treatment approach from the time of diagnosis OR following initial treatment with a parenteral anticoagulant

Prescribing the XARELTO® Starter Pack

  • To prescribe, simply write “XARELTO® Starter Pack for DVT and/or PE treatment. Take as directed.”
  • First 30 days of XARELTO® treatment included, with easy-to-follow dosing instructions2:
    • 15 mg twice daily with food (42 tablets total) for the first 21 days
    • 20 mg once daily with food (9 tablets total) for Days 22-30
  • No cost to elgible patients when used with the Janssen CarePath Trial Offer for XARELTO®. Terms and conditions apply
  • Available through retail and outpatient pharmacies

 

Indications

 

IMPORTANT SAFETY INFORMATION

 

Indication and Important saftey Information

 

  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.

References:

  1. Limone BL, Hernandez AV, Michalak D, Bookhart BK, Coleman CI. Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials. Thromb Res. 2013;132(4):420-426.
  2. Data on file. Janssen Pharmaceuticals, Inc. Data as of 8/8/14.